药品信息:
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(201921422013431.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- 部分中文Bondronat处方资料(仅供参考)
【英文名称】Bondronat
【适用证】
- 预防乳腺癌和骨转移患者的骨骼事件(病理性骨折,需要放疗或手术的骨并发症)
-有或没有转移的肿瘤诱导的高钙血症的治疗。
【禁忌症】
用于输注溶液的Bondronat浓缩物不得用于已知的对药物物质或任何赋形剂的超敏感性。
已知对已知对其他双膦酸盐过敏的患者应谨慎。
由于缺乏临床经验,不应在儿童中使用用于输注溶液的Bondronat浓缩液
【用法用量】
预防乳腺癌和骨转移患者的骨骼事件乳腺癌和骨转移患者预防骨骼事件的推荐剂量为:每3-4周静脉注射6 mg。 剂量应在1小时内输注。 在23例严重肾功能不全(CLcr <30 ml / min)的患者中,推荐剂量为每3-4周给予2 mg,输注超过1小时
【INDICATIONS AND USAGE】
- Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.
- Treatment of tumour-induced hypercalcaemia with or without metastases.
【Overdose】
Up to now there is no experience of acute poisoning with Bondronat concentrate for solution for infusion. Since both the kidney and the liver were found to be target organs for toxicity in preclinical studies with high doses, kidney and liver function should be monitored. Clinically relevant hypocalcaemia should be corrected by i.v. administration of calcium gluconate.
【CONTRAINDICATIONS】
Bondronat concentrate for solution for infusion must not be used in known hypersensitivity to the drug substance or to any of the excipients.
Caution is indicated in patients with known hypersensitivity to other bisphosphonates.
Bondronat concentrate for solution for infusion should not be used in children because of lack of clinical experience
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(201921422013431.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- |